Therapeutic | Crovalimab |
Target | C5 |
Heavy Chain | QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK |
100% seqID Fv Structure | 5b71 [Fvs: BA, DC] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 5b71 [Fvs: BA, DC] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-I/II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Chugai Pharmaceutical, Roche |
Conditions Approved | na |
Conditions Active | Paroxysmal nocturnal haemoglobinuria |
Conditions Discontinued | na |
Notes |